Over the past 1.5 years, we have seen a steady increase in the number of clients asking questions about how they can apply generative artificial intelligence (GenAI) and large language models (LLMs) to any business problem available to them. The excitement about GenAI has caused executive ...

A lot of clients are exploring the potential of generative machine learning models (LLMs or GenAI) for various use-cases, and the consistent question that comes up is whether they should utilize a third-party LLM API like OpenAI, Google’s Gemini, Anthropic’s Claude, or Cohere or any of the myriad ...

The global biotechnology market was valued at $1.55 trillion in 2023 and is projected to grow at a rate of 13.96% annually until 2030. We regularly look at the headlines of start-ups in the space securing funding and what that will enable them to pursue as a company, but we don’t often get a chance ...

Next-generation sequencing (NGS) is an emerging technology to determine DNA/RNA sequences for whole genome or specific regions of interest at a lower cost than traditional sequencing and a major disruptor in the biotech space. With NGS data having a major impact in the field of genomics research, ...

We were delighted to be joined on the Data in Biotech podcast by Wolfgang Halter from Merck Life Science for a deep dive into Bayesian Optimization for design of experiments (DOE). This approach to setting up experimental campaigns to leverage the information gained from previous experiments to ...

The potential impact of AI on the diagnosis and development of treatment for neurological diseases is significant. In August last year, a study demonstrated how AI could detect markers of Parkinson’s disease up to seven years before any symptoms appeared. This is the tip of the iceberg, and in our ...

Real-world data (RWD) is having a significant impact on biotech, pharma, and healthcare. Along with giving additional insight into clinical trials that will help to improve patient outcomes, McKinsey estimates that, over the next three to five years, an average top-20 pharmaceutical company could ...

One of the great things about the Data in Biotech podcast is that we get to look in depth at so many aspects of data science impacting the biotech and pharma space. This episode looked at the topic of knowledge graphs, what they are, why they are useful, and how LLMs, AI, and Machine learning are ...

With MarketsandMarkets forecasting that the health data market will reach $900 million by 2028, it was fantastic to sit down with Vera Mucaj, CSO at Datavant, to discuss how data is changing the healthcare landscape. Her background gives her real insight into both the scientific and technological ...

As we have often seen with guests who are founders, the inspiration for their business proposition is rooted in frustrations they have encountered in previous roles. Harry Rickerby, Co-Founder and CEO at Briefly Bio, is no exception. He talks about his new venture and the challenges that led him to ...

One of the goals of Data in Biotech is to build a community of professionals interested in how data can impact biotech organizations and create a space for discussion. Only one month in, we are starting to see that community grow as one of our previous guests, Markus Gershater from Synthace, put us ...

Tommy Tang is one of the most prominent online voices on computational biology. Tommy speaks to Data in Biotech on a range of topics, from his early career to growing a team and from the challenges of bioinformatics data to the potential of the cloud, we take a close look at the discipline of ...

If you are looking for a step-by-step discussion on some of the data pain points of clinical trials, then the episode of Data in Biotech with Miguel Cacho Soblechero is a great starting point. Looking at every stage, we sat down to discuss the challenges of clinical trials and the direction data ...

With a rich background in both academia and industry, Michelle Wiest provided fascinating insight into her current role assisting with the development and marketing of early blood-based cancer diagnostics. The conversation covered a lot of ground, from a whistlestop tour of her career to how she ...

One of the great things about looking at Data in Biotech is the variety within the industry. Having looked at regulation, digital twins, and real-human data, our conversation with Markus Gershater, co-founder at Synthace looks at the design of experiments and how this influences the management of ...

We are thrilled to have recently launched our new podcast ‘Data in Biotech’ with some of the leading thinkers in the field giving their take on industry challenges and trends. To accompany each podcast, this blog series will pick out the highlights of each episode and cover additional topics using ...

On this episode of Data in Biotech, we’re excited to be joined by Pradeep Ravindra, Associate Director, Data Analytics, Manufacturing from Lyell Immunopharma.

On this episode of Data in Biotech, we’re excited to be joined by Markus Gershater, Chief Scientific Officer and CoFounder of Synthace - a digital experiment platform built for high-performance life science R&D teams to help them run more powerful experiments and accelerate scientific progress.

On this episode of Data in Biotech, we’re excited to be joined by Michelle Wiest, Director of IVD Biostatistics at Freenome - a high-growth biotech company that creates tools to help prevent, detect, and treat disease.

It’s an arbitrary measurement, but the ‘first 100 days’ has become a benchmark for judging the success of new initiatives, such as a data platform. Originally used to gauge the success of new U.S. Presidents, the first 100 days are now widely used as a yardstick in businesses to measure upfront ...

You wouldn’t take on a new employee, pay them a salary and then ask them to sit back and take it easy. Yet, many enterprises do this with their data. They invest in data management and storage to meet regulatory requirements, but it sits within the organization underutilized and becomes ‘lazy’ data.

Data is a double-edged sword. Unharnessed, businesses can feel swamped and bogged down by the vast volumes of data generated. They are often obligated to maintain and store it but derive little value from it. In fact, without an appropriate data strategy in place, businesses can see increasing ...

Every business relies on marketing to succeed. But not every business has a dedicated marketing team or in-depth knowledge of how to successfully reach both new and existing customers to increase sales. One common challenge is that each lead is at a different place in your sales funnel - why would ...

Your company’s data is one of its most valuable assets. While the promise of automated machine learning and data mining seem attractive, your company will still need people to help you generate value from data for the foreseeable future.

Is your legacy software buckling under the weight of your data? Digital tools are increasingly becoming inseparable from your business outcomes. Your company is either growing or dying, and data is its lifeblood. Though many organizations see the value of digital transformation, they too often ...

Data is the lifeblood of modern companies and companies are creating more data than ever before. Hospitals now rely on electronic medical records to record and monitor interactions with patients, identify risk factors, and recommend treatments. Retailers utilize purchase data to recommend products, ...

Budgeting is easy for fixed costs and relatively simple for variable costs, as long as you know the drivers of the variable expense, such as number of products sold or parcels shipped.

Top e-commerce companies have the capacity to monitor and understand their business in multiple areas, and their leaders know where they need to improve and where they excel. In today’s competitive business environment, those companies who spend the time asking the right questions about their ...

Two of the most important metrics for evaluating the performance of your business are the average Customer Acquisition Cost (CAC) of your customers and the expected Lifetime Value (LTV) of those customers.